Samplix and Innokas Medical to unlock the genome with development of Xdrop™ instrument

A Danish company Samplix ApS selected Innokas Medical to co-create the novel Xdrop™ instrument for droplet-based PCR-free enrichment of genomic regions.

Samplix ApS, founded in 2012 in Denmark, aspire to become a leading provider of next generation solutions for PCR-free target enrichment and amplification of single molecules for high fidelity molecular biology research. The company has recently introduced their latest innovation, Xdrop™ instrument, into the market.

‘We are a provider of tools for high fidelity molecular biology research. Our aim has been to develop a tool that can enable scientists to reveal the true biological representation where genomic variation is extremely rare and the target region is practically unknown,’ said Marie Mikkelsen, CTO at Samplix.

‘We decided to develop a workflow based on compartmentalization of single molecules in droplets without the need for PCR amplification. After 6 years of product development and thorough testing, a fully developed system for droplet-based PCR-free enrichment of genomic regions, named Xdrop™, was commercially introduced in September 2019,’ continued Mikkelsen.

In practice, the Xdrop™ instrument is a droplet generator that can produce droplets with the use of specific microfluidics dPCR and dMDA cartrides. It is operated from the touch screen and droplet generation is fully automated. Samplix also offers a complete range of reagents, cartridges and accessories to use with the Xdrop™ instrument.

Better outcome by co-creation

Samplix and Innokas Medical started design and development related co-operation in the end of 2018, when Samplix chose Innokas Medical as their co-creation partner to develop the final commercial version of their innovation.

‘When our technology matured to the stage where we needed mass manufacturing of our instruments, we contacted a range of different companies to assess their OEM capabilities. Innokas Medical was selected based on having solid internal development capabilities including project management, mechanical, hardware and software engineering, as well as FDA approved production facilities capable of high-volume manufacturing at a competitive cost,’ said Mikkelsen.

Petri Jolma, a Project Manager, states that Innokas has been able to create concrete and valuable benefits to Samplix because the company has all the needed competencies in house to support Samplix’s project.

‘During the past year of working with Innokas Medical we have had very positive experiences. The team is very professional, following good project management practice, and we have had a good communication with the entire team throughout the project. We have experienced a high degree of transparency in all matters relating to the project giving us confidence in timelines, risks, quality, and pricing structure. It has been a pleasure working with Innokas and we are looking forward to our continued collaboration,’ she concluded.

Source: Innokas Medical

← Back to news & blogs